Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years

Cancer

Volumn 98, Issue 7, 2003, Pages 1504-1513

  Li, Christopher I ^a,b   Malone, Kathleen E ^a,b   Weiss, Noel S ^a,b   Boudreau, Denise M ^c   Cushing Haugen, Kara L ^a   Daling, Janet R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Adrenergic antagonists; Angiotensin converting enzyme inhibitors; Breast neoplasms; Calcium channel blockers; Diuretics

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ISRADIPINE; METOPROLOL; NADOLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PINDOLOL; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; THIAZIDE DIURETIC AGENT; TIMOLOL; UNINDEXED DRUG; VERAPAMIL;

AGED; AGING; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CANCER RISK; CONTROLLED DRUG RELEASE; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG USE; EDUCATION; FEMALE; HUMAN; HYPERTENSION; IMMEDIATE DRUG RELEASE; LOGISTIC REGRESSION ANALYSIS; MARRIAGE; PARITY; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS; SUSTAINED RELEASE PREPARATION;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; ODDS RATIO; POPULATION SURVEILLANCE; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 0141563692     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11663     Document Type: Article

References (29)

1. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens. 1996;9:713-714.
2. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493-497.
3. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80:1438-1447.
4. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens. 1998;16:119-124.
5. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997; 349:525-528.
6. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses' Health Study. Cancer. 1998;83: 2003-2007.
7. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA. 1998;279:1000-1004.
8. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med. 2000;160:349-353.
9. Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer. 2000;89:165-170.
10. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92: 2462-2470.
11. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29:1091-1094.
12. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179-184.
13. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393-1396.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-2997.
15. Muti P, Stanulla M, Micheli A, et al. Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes Control. 2000;11:721-730.
16. Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord. 2002;26: 747-753.
17. Antonios TF, MacGregor GA. Some similarities and differences between verapamil and the dihydropyridines. J Hypertens. 1998;16(Suppl):S31-S34.
18. Breslow NE, Day NE. Statistical methods in cancer research, volume I. In: Davis W, editor. The analysis of case-control studies. Lyon: IARC Scientific Publications, 1980:5-338.
19. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol. 1982; 116:114-122.
20. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol. 1992;45:683-692.
21. Sjahid SI, van der Linden PD, Stricker BH. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam Elderly Study. Br J Clin Pharmacol. 1998;45:591-595.
22. Kehoe R, Wu SY, Leske MC, Chylack LT Jr. Comparing self-reported and physician-reported medical history. Am J Epidemiol. 1994;139:813-818.
23. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh JE. Active cell death in hormone-dependent tissues. Cancer Metast Rev. 1992;11:197-220.
24. Connor J, Sawczuk IS, Benson MC, et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate. 1988;13:119-130.
25. Juntti-Berggren L, Larsson O, Rorsman P, et al. Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. Science. 1993;261:86-90.
26. Ray SD, Kamendulis LM, Gurule MW, Yorkin RD, Corcoran GB. Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J. 1993;7:453-463.
27. Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2002;11:1361-1368.
28. Eriksson JW, Fowelin J, Urbanavicius V. Insulin concentrations and insulin sensitivity after short-term amiloride in healthy subjects. Eur J Clin Pharmacol. 1994;46:469-472.
29. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand. 1983;213:27-30.